Ovarian Leydig Cell Tumor: Cause of Virilization in a Postmenopausal Woman

Nádia Mourinho Bala, José Maria Aragüés, Silvia Guerra, Delfina Brito, Cristina Valadas

Corresponding Author: Nádia Mourinho Bala, e-mail: nadia.bala@hbeatrizangelo.pt

Conflict of interest: None declared

Patient: Female, 77-year-old
Final Diagnosis: Ovarian Leydig cell tumor
Symptoms: Hirsutism
Medication: —
Clinical Procedure: —
Specialty: Endocrinology and Metabolic

Objective: Rare disease
Background: Only 0.5% of all ovarian tumors are Leydig cell tumors and they are generally benign and unilateral. These androgen-secreting tumors lead to virilizing symptoms, most often in postmenopausal women. Because Leydig cell tumors are typically small, diagnosing them accurately can be challenging.

Case Report: We report the case of a 77-year-old woman who was referred to our Endocrinology Clinic because of a 5-year history of hirsutism (Ferriman-Gallwey score of 11) with no discernible cause. The patient had high levels of serum testosterone and a normal level of dehydroepiandrosterone sulfate. Imaging, including transvaginal ultrasound and pelvic magnetic resonance, revealed a 16-mm uterine nodule, which was suspected to be a submucous leiomyoma, but no adrenal or ovarian lesions. Despite the lack of findings on imaging and because of the high suspicion for an androgen-secreting ovarian tumor, bilateral laparoscopic oophorectomy was performed. Histological examination of the specimen revealed a non-hilar Leydig cell tumor that measured 8 mm in its largest axis. After the surgery, the patient had significant clinical improvement and her laboratory test results normalized. Her sister had the same symptoms and laboratory findings at a similar age, which raised the suspicion of a possible familial genetic syndrome. No genetic testing was performed, however, because the patient’s sister declined further diagnostic investigation.

Conclusions: Leydig cell tumors are rare, and even when they are small, they can cause symptoms related to androgen excess. As a result, diagnosing them often is challenging.

Keywords: Hyperandrogenism • Leydig Cell Tumor • Postmenopause

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/933126
Background

The appearance of a few terminal hairs on the face and a decrease in body and scalp hair in women during menopause are considered part of the natural process following cessation of menses [1,2]. The appearance of virilizing features in a menopausal patient, such as male alopecia, clitoromegaly, a deep voice, acne, increased libido, and hirsutism, however, should lead to an investigation. These symptoms can be due to adrenal tumors, including androgen-secreting carcinomas, and ovarian tumors. Leydig cell tumors are rare ovarian neoplasms classified as sex cord-stromal tumors and they can cause hyperandrogenism. Only 0.5% of all ovarian tumors are Leydig cell tumors and most are benign and unilateral [3]. Diagnosing them can be challenging because they may be symptomatic despite their small size and they often are not detected on imaging.

Case Report

We report the case of a 77-year-old woman with a history of autoimmune hepatitis, type 2 diabetes, dyslipidemia, and Hashimoto thyroiditis. She was taking azathioprine (50 mg bid) and was not receiving any treatment associated with hirsutism, including glucocorticoids. She had a history of 4 uncomplicated pregnancies and experienced menopause at age 42 years. She had not taken hormone replacement therapy.

Over the past 4 years, the patient had experienced generalized hirsutism, which was most prominent on her face (Ferriman-Gallwey score of 11), and caused her significant psychological distress. Laboratory testing revealed the following levels: total testosterone 290 ng/dL (normal range, <41), free testosterone 5.60 ng/mL (normal range, 0.10-4.70), delta-4 androstenedione 2.9 ng/mL (normal range, 0.4-3.7), 17-hydroxyprogesterone 1.80 ng/mL, dehydroepiandrosterone sulfate (DHEAS) 72 ug/dL (normal range, 26-460), thyroid stimulating hormone 5.60 ng/mL (normal range, 0.10-4.70), and free T4 16.0 pmol/L (normal range, 0.3-3.7). The patient’s sister underwent pelvic MRI, which showed normal-sized ovaries and no large lesions. A bilateral oophorectomy was recommended, but she declined the treatment.

Discussion

It is important to note that the patient’s sister had the same symptoms of marked hirsutism, at age 79 years. Her serum levels were as follows: total testosterone 258 ng/dL (normal range, <41), free testosterone 3.30 ng/mL (normal range, 0.10-4.70), serum hormone binding globulin 61.0 nmol/L (normal range, 18.0-144.0), DHEA-S 84 ug/dL (normal range, 26-460), and delta-4 androstenedione 3.1 ng/mL (normal range, 0.3-3.7). The patient’s sister underwent pelvic MRI, which showed normalized ovaries and no large lesions. A bilateral oophorectomy was recommended, but she declined the treatment.

Accurately diagnosing virilizing ovarian tumors is often challenging because they may be too small to detect on imaging. Identifying small functioning can require use of multiple types of imaging and an integrated approach. TVUS is often used as a good first-line exam and pelvic MRI adds to clear characterization of the ovarian anatomy. However, even both types of imaging together can be insufficient if a tumor is very small.

In the patient in our case, a normal serum DHEA-S level excluded adrenal causes of hyperandrogenism, leaving an ovarian androgen-secreting tumor as the most likely diagnosis. For this reason, an oophorectomy was recommended. After the surgery, the patient’s symptoms improved and her serum testosterone levels normalized. The histopathological examination supported the diagnosis of a non-hilar Leydig cell tumor, which is considered a steroid cell tumor. Such tumors are defined as ovarian neoplasms, composed of steroid hormone-secreting cells, and divided into 3 subtypes: stromal luteomas arising from ovarian stroma, Leydig cell tumors arising from Leydig cells in the hilum, and steroid cell tumors not otherwise specified when the lineage of the tumor is unknown [4]. This latter subtype is the most common, accounting for 80% of steroid cell tumors [5,6]. Usually, Leydig cell tumors arise from the ovarian hilum. Non-hilar Leydig cell tumors, as in our patient, occur in ovarian cortical stroma and can be difficult to distinguish from other stromal tumors [7].

Pure Leydig cell tumors of the non-hilar type closely resemble the stromal luteoma, a distinctive form of lipid cell tumor described by Scully [8]. It is distinguished from a stromal luteoma by the presence of characteristic crystalloids of Reinke within the tumor cells [8,9]. These tumors secrete androgens, which are responsible for virilizing symptoms, and they are usually unilateral and benign. However, there is a risk of malignant transformation. About 20% of patients develop metastasis, usually limited to the peritoneal cavity; metastasis to distant sites is rare [10]. Because the patient’s sister had the same symptoms and laboratory findings at a similar age, we suspected a familial genetic syndrome. However, no histologic
diagnosis was confirmed for her because she declined surgery and genetic testing was not performed. In her case, therapy with spironolactone was provided.

Recent data indicate that germline or somatic mutations in some genes can lead to the development of some types of sex cord-stromal ovarian tumors [11]. DICER1 syndrome, which includes pleuropulmonary blastoma, thyroid gland neoplasia, pulmonary cysts, and cystic nephromas and is associated with Sertoli-Leydig tumors, is caused by a mutation in the DICER1 gene. Some types of sex cord-stromal tumors also can be associated with a mutation in the STK11 gene, which is associated with Peutz-Jeghers syndrome. This syndrome can include the presence of hamartomatous polyposis in the gastrointestinal tract and melanocytic macules. Mutations in the FOXL2 gene can be found in almost all adult granulosa cell tumors [11]. Any of the genetic syndromes described above could be associated with our patient’s case.

Conclusions

Leydig cell tumors are rare, challenging to diagnose, and should be considered in the differential for virilizing symptoms.

**Table 1.** Laboratory evaluation before and after surgery.

|                | Total testosterone (ng/mL, RR <41) | Free testosterone (ng/dL, RR 0.10-4.70) | SHBG (nmol/L, RR 18.0-144.0) | DHEA-S (ug/dL, RR 26-460) |
|----------------|------------------------------------|----------------------------------------|------------------------------|---------------------------|
| Presurgical    | 290                                | 5.60                                   | 35                           | 60                        |
| Postsurgical   | <12                                | 3.0                                    |                              |                           |

SHBG – sex hormone binding globulin; DHEA-S – dehydroepiandrosterone sulfate; RR – reference range.

**Figure 1.** Histopathological images. (A) Hematoxylin-eosin staining showing the tumor. (B) Arrowhead showing Reinke crystalloids. (C) Positive staining of tumor cells for calretinin (20). (D) Positive staining of tumor cells for inhibin (20).
in postmenopausal women. The diagnosis is based on clinical history, laboratory findings, and imaging. After an adrenal cause of hyperandrogenism has been excluded, even in the absence of ovarian lesions, oophorectomy should be considered.

Conflict of Interest
None declared.

References:
1. Alpañés M, González-Casbas JM, Sánchez J, et al. Management of postmenopausal virilization. J Clin Endocrinol Metab. 2012;97(8):2584-88
2. Thomas PK, Ferriman DG. Variation in facial and pubic hair growth in white women. Am J Phys Anthropol. 1957;15(2):171-80
3. Lantzsch T, Stoerer S, Lawrenz K, et al. Sertoli-Leydig cell tumor. Arch Gynecol Obstet. 2001;264(4):206-8
4. Hayes MC, Scully RE. Ovarian steroid cell tumors (not otherwise specified). A clinicopathological analysis of 63 cases. Am J Surg Pathol. 1987;11(11):835-45
5. Outwater EK, Wagner BJ, Mannion C, et al. Sex cord-stromal and steroid cell tumors of the ovary. Radiographics. 1998;18(6):1523-46
6. Jiang W, Tao X, Fang F, et al. Benign and malignant ovarian steroid cell tumors, not otherwise specified: Case studies, comparison, and review of the literature. J Ovarian Res. 2013;6:63
7. Rabban JT, Soslow RA, Zaloudek CZ. Chapter 16 – Immunohistology of the female genital tract. In: Diagnostic Immunohistochemistry. 2010;690-762
8. Scully RE. Stromal luteoma of the ovary. A distinctive type of lipid-cell tumor. Cancer. 1964;17(6):769-78
9. Sternberg WH, Roth LM. Ovarian stromal tumors containing Leydig cells. Cancer. 1973;32(4):940-51
10. Apelt-Alcalay D, Reyna-Villasmil E. Pure Leydig cell tumor of the ovary in a premenopausal woman. Rev Peru Ginecol Obst. 2020;66(2):v66i2257
11. Macut D, Ilić D, Mitrović Jovanović A, Bjekić-Macut J. Androgen-secreting ovarian tumors. Front Horm Res. 2019;53:100-7

Declaration of Figures Authenticity
All figures submitted have been created by the authors who confirm that the images are original with no duplication and have not been previously published in whole or in part.